Despite its low incidence, MET amplification is involved in CRC relapse after multiple anti-EGFR therapies, as HGF activates RTK-associated signaling pathways independent of EGF in mediating CRC growth8,24,26. This evidence concerns the gene MET and colorectal carcinoma.